EPHA2 and cancer: Thus, EphA2 remains a promising but under‐utilized target for Ab‐based cancer therapeutics, and we reasoned that the development of a more extensive toolkit of Abs with detailed structural knowledge could provide a better understanding of EphA2 signaling and potentially could enable the development of more efficacious therapeutics with better safety profiles.